Ewing sarcoma (ES) is rare in Japanese people, and only 30–40 patients develop the
disease annually. To diagnose ES, molecular techniques that aim to detect characteristic …

BACKGROUND. Advances in systemic and local therapies have improved outcomes for
patients with the Ewing sarcoma family of tumors (ESFT). As new treatments are developed …

PURPOSE: To further elaborate on prognostic factors for Ewing's sarcoma of bone and to
document improvements in relapse-free survival (RFS) and trends in local therapy over the …

Purpose: The impact of different local therapy approaches on local control, event-free
survival, and secondary malignancies in the CESS 81, CESS 86, and EICESS 92 trials was …

BACKGROUND An excess risk of second malignancies has been reported in survivors of
Ewing's sarcoma. We examined a multiinstitutional data base to reevaluate the risk among …

PURPOSE: The identification of prognostic factors in patients with nonmetastatic Ewing's
sarcoma could allow the use of risk-adapted therapeutic strategies of treatment. PATIENTS …

PURPOSE This study was performed to assess the prognostic value of the proposed
histopathologic method to evaluate the response of the primary tumor to preoperative …

Seventy-four patients who had a Ewing sarcoma of bone were managed with preoperative
and postoperative chemotherapy and operative resection, with or without postoperative …

Abstract Monoclonal antibody (MAb) HBA71, which was raised against Ewing's sarcoma
cells, recognizes a cell-surface glycoprotein, p30/32MIC2, that is encoded by the MIC2 gene …

PURPOSE To investigate the possibility that the substitution of ifosfamide for
cyclophosphamide therapy for Ewing's sarcoma will improve survival over that seen in the …